Your browser doesn't support javascript.
loading
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
Nowak, A K; Cook, A M; McDonnell, A M; Millward, M J; Creaney, J; Francis, R J; Hasani, A; Segal, A; Musk, A W; Turlach, B A; McCoy, M J; Robinson, B W S; Lake, R A.
Affiliation
  • Nowak AK; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth anna.nowak@uwa.edu.au.
  • Cook AM; School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth.
  • McDonnell AM; School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth.
  • Millward MJ; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth School of Medicine and Pharmacology.
  • Creaney J; School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth.
  • Francis RJ; School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth Department of Nuclear Medicine.
  • Hasani A; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth.
  • Segal A; PathWest and.
  • Musk AW; School of Medicine and Pharmacology Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth School of Population Health.
  • Turlach BA; Centre for Applied Statistics, University of Western Australia, Perth.
  • McCoy MJ; School of Medicine and Pharmacology St John of God Hospital, Perth, Australia.
  • Robinson BW; School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth.
  • Lake RA; School of Medicine and Pharmacology National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth.
Ann Oncol ; 26(12): 2483-90, 2015 Dec.
Article in En | MEDLINE | ID: mdl-26386124
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / CD40 Antigens / Pemetrexed / Lung Neoplasms / Mesothelioma / Antibodies, Monoclonal Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2015 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / CD40 Antigens / Pemetrexed / Lung Neoplasms / Mesothelioma / Antibodies, Monoclonal Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2015 Type: Article